Premier Asset Management LLC Cassava Sciences Inc Transaction History

Premier Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $662,455 - $2.14 Million	-15,852 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $43,788 - $122,198	1,362 Added 9.4%	15,852 $1.35 Million
Q1 2021 May 12, 2021	SELL	$7.09 - $87.95 $452,072 - $5.61 Million	-63,762 Reduced 81.48%	14,490 $652,000
Q4 2020 Feb 16, 2021	BUY	$6.79 - $12.25 $281,533 - $507,921	41,463 Added 112.7%	78,252 $534,000
Q3 2020 Nov 16, 2020	BUY	$2.86 - $11.51 $105,216 - $423,441	36,789 New	36,789 $423,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $160M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Premier Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Premier Asset Management LLC with notifications on news.